- Home
- KOD
as 11-21-2024 12:37pm EST
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
Upcoming Earnings Alert:
Get ready for potential market movements as Kodiak Sciences Inc KOD prepares to release earnings report on 26 Nov 2024.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 186.3M | IPO Year: | 2018 |
| Target Price: | $3.50 | AVG Volume (30 days): | 420.1K |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.19 - $7.77 | Next Earning Date: | 11-26-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kodiak Sciences Inc News
KOD Breaking Stock News: Dive into KOD Ticker-Specific Updates for Smart Investing
Zacks
6 days ago
Kodiak Q3 Loss Narrower Than Expected, Pipeline Development in Focus
PR Newswire
7 days ago
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2024 Financial Results
PR Newswire
10 days ago
Kodiak Sciences to Participate in Upcoming Investor Conferences
Simply Wall St.
a month ago
3 US Penny Stocks With Market Caps Under $500M To Consider
PR Newswire
a month ago
Kodiak Sciences to Present at Innovate Retina 2024
Zacks
a month ago
Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks
PR Newswire
2 months ago
Kodiak Sciences to Host Investor R&D Day Today at 10:30am Eastern Time
Simply Wall St.
2 months ago
We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Compare KOD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KOD Kodiak Sciences Inc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.